Discovery of Novel Analgesics-A biotechnology company

Pioneering Breakthrough Therapies to Redefine Pain Management

Learn more ⇀

Scroll down

About us

Iongen Therapeutics Co., Ltd. is a company exclusively focuses on ion channel targets to develop innovative pain therapeutics for unmet clinical needs. Our robust pipeline includes two best-in-class lead Nav1.8 inhibitors advancing through IND-enabling studies, alongside a synergistic Nav1.7/1.8 dual inhibitor and novel Nav1.8 inhibitor-ion channel modulator combinations—all engineered to deliver superior efficacy for chronic pain management. Rooted in scientific rigor and clinical relevance, we strive to pioneer breakthrough therapies that redefine the global standard of care for pain patients.

Learn more +

Pain: an unpleasant sensory and emotional experience associated with actual or potential tissue damage

Acute pain

Sudden onset, often sharp or intense
Linked to identifiable injury or illness
Time-limited, typically resolving with healing
Usually lasts less than three months
Treatment targets the underlying cause

Chronic pain

May be constant or intermittent
Varies in intensity
A condition independent of a specific illness or injury
Not connected to any perceived threat or danger
Lasts more than three months
Treatment requires addressing physical, mental, and social factors

Global Market: Globally, 1 in 5 people suffers from chronic pain.

According to Mordor Intelligence, the global pain management market is projected to reach 78.12 billion in 2024 and expand to 93.19 billion by 2029, growing at a CAGR of 3.59% during the forecast period.

Market Growth: Asia Pacific region shows highest potential.

With the increasing aging population and healthcare infrastructure development, the demand for pain management drugs and devices is skyrocketing in the APAC region significantly.

Corporate Milestones

• Company incorporated. • Core team established with drug discovery expertise. • Successfully closed an angel funding round raising tens of millions RMB.

2021

• Successfully closed an angel funding round raising tens of millions RMB. • State-of-the-art lab facility operational. • Core R&D programs.

2022

• Strengthened organizational capacity. • Pipeline milestones progressing as planned. • Awarded "Technology-based SME title".

2023

• Focuson pain management. • Completed Pre-A round financing.

2024

• Initiate three IND-enabling studies. • Further strengthen the team and enhance corporate R&D capabilities. • Initiate Series A fundraising and BD engagements.

2025

• Successfully completed Series A financing. • Advanced four leading pipeline assets into clinical-stage development. • Continued to build a world-class team and proprietary technology platform. • Maintained active and strategic business development engagements.

2026

Team

Xiaoguang Lei, PhD

Founder

• Professor, College of Chemistry and Molecular Engineering, Peking University • Pioneering research in chemical biology, translational medicine, and innovative drug discovery

Yong Yang, MD

Co-Founder

• Vice President of Hospital for Skin Diseases, Chinese Academy of MedicalSciences • First to demonstrate Naᵥ 1.7's pathophysiological role in erythromelalgia

Shun Su, PhD

CSO

• Former Principal Scientist at Bristol Myers Squibb • Proven expertise in small-molecule drug discovery

Daohong Liao, PhD

COO

• Former senior researcher at Pharmaron and Department of New Drug R&D, PKUSIM • Broad experiences spanning Med Chem to CMC

Bingjie Wang, PhD

CBO

• Former biotech investor • Experienced in high-profile projects and portfolio management

Want more product service? Leave us a message

We will contact you within one working day. Please pay attention to your email.

www.iongentherapeutics.com

en.iongentherapeutics.com

0086-25-58881910

E-mail: liaoyunzhi@iongenpharm.com

COOKIES

Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy

COOKIES

required

These cookies are necessary for basic functions such as payment. Standard cookies cannot be turned off and do not store any of your information.

analyze

These cookies collect information, such as how many people are using our site or which pages are popular, to help us improve the customer experience. Turning these cookies off will mean we can't collect information to improve your experience.

Feature

These cookies enable the website to provide enhanced functionality and personalization. They may be set by us or by third-party providers whose services we have added to our pages. If you do not allow these cookies, some or all of these services may not function properly.

advertise

These cookies help us understand what you are interested in so that we can show you relevant advertising on other websites. Turning these cookies off will mean we are unable to show you any personalized advertising.

Business License